AI Financial Corp 10-Q for FY2026 Q3
AI Financial Corp (AIFC)
About this 10-Q
AI Financial Corp filed this 10-Q on November 12, 2026, covering the quarter ended September 26, 2026 (FY2026 Q3).
AI Financial Corporation recorded a $637.2 million unrealized loss on cryptocurrency assets for the 39 weeks ended September 26, 2026, while disclosure controls and internal control over financial reporting were ineffective. Continuing-operations revenue fell 24.4% to $0.9 million. AI summary
Headline figures
Quarter ended September 26, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $248K
- down 72.8% from $913K a year earlier
- Net loss
- $18.18M
- compared with net income of $48.96M a year earlier
- Diluted EPS
- -$0.13
- compared with $0.29 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
| Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For
the quarterly period ended
or
| Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
Commission
File No.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The | ||||
| (The Nasdaq Capital Market) |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days. ☒
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |
| ☒ | Smaller reporting company | |||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes
As of November 9, 2026, there were outstanding shares of the registrant’s common stock, with a par value of $.
AI FINANCIAL CORPORATION
INDEX TO FORM 10-Q
| 2 |
PART I. FINANCIAL INFORMATION
ITEM 1. Condensed Consolidated Financial Statements
AI FINANCIAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per-share amounts)
| September 26, 2026 | December
27, 2025* | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Cash | $ | $ | ||||||
| Short term investment | ||||||||
| Trade and other receivables, net | ||||||||
| Digital assets receivable | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Other current assets | ||||||||
| Current assets from discontinued operations | ||||||||
| Total current assets | ||||||||
| Property and equipment, net | ||||||||
| Intangible assets, net | ||||||||
| Cryptocurrency assets, at fair value | ||||||||
| Deferred income taxes, net | ||||||||
| Goodwill | ||||||||
| Notes receivable, net | ||||||||
| Other assets from discontinued operations | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities, Mezzanine Equity and Stockholders’ Equity (Deficit) | ||||||||
| Liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued liabilities - other | ||||||||
| Convertible debentures | ||||||||
| Notes payable | ||||||||
| Current liabilities from discontinued operations | ||||||||
| Total current liabilities | ||||||||
| Notes payable | ||||||||
| Other noncurrent liability | ||||||||
| Noncurrent liabilities from discontinued operations | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (Note 14) | ||||||||
| Mezzanine equity | ||||||||
| Series S preferred stock — convertible component classified in mezzanine equity (Note 17) | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, series A-1 - par value $ per share authorized, shares issued and outstanding at September 26, 2026 and December 27, 2025 | ||||||||
| Preferred stock, series B - par value $ per share, authorized, shares issued and outstanding at September 26, 2026 and December 27, 2025 | ||||||||
| Convertible preferred stock, series I - par value $ per share, authorized, and shares issued and outstanding at September 26, 2026 and December 27, 2025 | ||||||||
| Preferred stock, series M - par value $ per share, authorized, shares issued and outstanding at September 26, 2026 and December 27, 2025 | ||||||||
| Preferred stock, series Q - par value $ per share, authorized, and shares issued and outstanding at September 26, 2026 and December 27, 2025 | ||||||||
| Series S preferred stock— permanent equity component (Notes 16 and 17) | ||||||||
| Convertible preferred stock, series V - par value $ per share, authorized, and shares issued and outstanding at September 26, 2026 and December 27, 2025, respectively | ||||||||
| Preferred stock, value | ||||||||
| Common stock, $ par; shares authorized; issued and outstanding at September 26, 2026; issued and outstanding at December 27, 2025 | ||||||||
| Treasury stock, at cost, and shares at September 26, 2026 and December 27, 2025, respectively | ( | ) | ||||||
| Accumulated other comprehensive income (loss) | ( | ) | ||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Equity attributable to AI Financial Corporation shareholders | ||||||||
| Noncontrolling interest | $ | $ | ||||||
| Total stockholder’s equity | ||||||||
| Total liabilities, mezzanine equity and stockholders’ equity | $ | $ | ||||||
| * |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Comparative 2025 amounts have been reclassified to present ALT5 Canada and Biotechnology as discontinued operations. Consolidated net income and total earnings per share are unchanged. Amounts may not sum due to rounding.
| 3 |
AI FINANCIAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(UNAUDITED)
(Dollars in thousands, except per-share)
| September 26, 2026 | September 27, 2025 | September 26, 2026 | September 27, 2025 | |||||||||||||
| For the Thirteen Weeks Ended | For the Thirty-Nine Weeks Ended | |||||||||||||||
| September 26, 2026 | September 27, 2025 | September 26, 2026 | September 27, 2025 | |||||||||||||
| Revenues | $ | $ | $ | $ | ||||||||||||
| Cost of revenues | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative expenses | ||||||||||||||||
| Operating loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income (expense), net | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Unrealized gain on exchange transactions | ||||||||||||||||
| Unrealized loss on crypto-currency assets | ( | ) | ( | ) | ||||||||||||
| Realized gain (loss) on exchange transactions | ||||||||||||||||
| Other income (expense), net | ( | ) | ( | ) | ( | ) | ||||||||||
| Total other (expense) income, net | ( | ) | ( | ) | ||||||||||||
| Loss before benefit (provision) for income taxes | ( | ) | ( | ) | ||||||||||||
| Income tax benefit (provision) | ( | ) | ( | ) | ||||||||||||
| Net income (loss) from continuing operations | ( | ) | ( | ) | ||||||||||||
| Loss from discontinued operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Income tax benefit (provision) from discontinued operations | ( | ) | ( | ) | ||||||||||||
| Net income (loss) from discontinued operations | ( | ) | ( | ) | ( | ) | ||||||||||
| Net income (loss) | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Other comprehensive income: | ||||||||||||||||
| Foreign currency translation and related reclassification adjustments | ||||||||||||||||
| Comprehensive income (loss) | ( | ) | ( | ) | ||||||||||||
Net income (loss) per share: | ||||||||||||||||
| Net income (loss) per share from continuing operations, basic | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Net income (loss) per share from continuing operations, diluted | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Net income (loss) per share from discontinued operations, basic | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||
| Net income (loss) per share from discontinued operations, diluted | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||
| Net income (loss) per share, basic | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Net income (loss) per share, diluted | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic | ||||||||||||||||
| Diluted | ||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 4 |
AI FINANCIAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(In thousands)
| September 26, 2026 | September 27, 2025 | |||||||
| For the Thirty-Nine Weeks Ended | ||||||||
| September 26, 2026 | September 27, 2025 | |||||||
| OPERATING ACTIVITIES: | ||||||||
| Net income (loss) from continuing operations | $ | ( | ) | $ | ||||
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Stock-based compensation | ||||||||
| Amortization and other noncash debt adjustments | ||||||||
| Amortization of right-of-use assets | ||||||||
| Unrealized gain/loss on cryptocurrency assets | ( | ) | ||||||
| Digital asset transaction adjustments | ( | ) | ||||||
| Realized gain on digital assets | ||||||||
| Change in deferred income taxes | ( | ) | ||||||
| Other | ( | ) | ( | ) | ||||
| Changes in assets and liabilities: | ||||||||
| Accounts receivable | ||||||||
| Digital assets receivable | ( | ) | ||||||
| Prepaid expenses and other current assets | ( | ) | ( | ) | ||||
| Accounts payable and accrued expenses | ( | ) | ||||||
| Digital assets payable | ( | ) | ||||||
| Operating cash flows from discontinued operations | ( | ) | ||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| INVESTING ACTIVITIES: | ||||||||
| Purchases of short-term certificates of deposit | ( | ) | ||||||
| Proceeds from redemption of certificates of deposit | ||||||||
| Purchases of property and equipment | ( | ) | ||||||
| Cash acquired in Mswipe acquisition | ||||||||
| Cryptocurrency assets purchased | ( | ) | ||||||
| Cryptocurrency assets redeemed | ||||||||
| Cash disposed of with ALT5 Canada | ( | ) | ||||||
| Net cash (used in) provided by investing activities | ( | ) | ( | ) | ||||
| FINANCING ACTIVITIES: | ||||||||
| Proceeds from equity financing | ||||||||
| Payments of placement fees | ( | ) | ||||||
| Purchase of treasury common shares | ( | ) | ||||||
| Proceeds from the issuance of notes payable | ||||||||
| Payments on notes payable | ( | ) | ( | ) | ||||
| Payments on related party notes payable | ( | ) | ||||||
| Financing cash flows from discontinued operations | ||||||||
| Net cash provided by financing activities | ||||||||
| Effect of changes in exchange rate on cash and cash equivalents | ||||||||
| (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | ||||||||
| CASH AND CASH EQUIVALENTS, beginning of period | ||||||||
| LESS CASH OF DISCONTINUED OPERATIONS, end of period | ||||||||
| CASH AND CASH EQUIVALENTS, end of period | $ | $ | ||||||
| Supplemental cash flow disclosures: | ||||||||
| Cash paid for interest (continuing and discontinued) | $ | $ | ||||||
| Noncash financing and investing activities: | ||||||||
| Common stock issued for Block Street asset acquisition | $ | $ | ||||||
| Common stock issued for prefunded warrants granted | $ | $ | ||||||
| Notes payable converted to common stock | $ | $ | ||||||
| Common stock issued for the acquisition of Mswipe | $ | $ | ||||||
| Common stock warrants issued for the acquisition of Mswipe | $ | $ | ||||||
| Drew common stock issued for the acquisition of Mswipe | $ | $ | ||||||
| Convertible Preferred Series Q shares converted to common stock | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 5 |
AI FINANCIAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(UNAUDITED)
(Dollars in thousands)
| Series A-1 Shares | Series A-1 Amount | Series S-1 Shares | Series S-1 Amount | Series B Shares | Series B Amount | Series I Shares | Series I Amount | Series M Shares | Series M Amount | Series Q Shares | Series Q Amount | Series V Shares | Series V Amount | Common Stock Shares | Common Stock Amount | Additional Paid-in Capital | Treasury Stock | Accumulated Deficit | Accumulated Other Comprehensive Income | Noncontrolling Interest | Total Stockholders’ Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, December 27, 2025 | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for Series Q convertible stock converted | — | — | — | — | ( | ) | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for Series I convertible stock converted | — | — | — | ( | ) | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for consulting agreement | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for Debenture converted | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued in lieu of notes payable obligation | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency adjustment | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prior period adjustment | — | — | — | — | — | — | — | — | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, March 28, 2026 | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treasury share buyback | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ALT5 Sigma Corp common stock issued for Block Street | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency adjustment | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 27, 2026 | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Consolidation and other equity adjustments | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency and noncompete basis adjustments | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reversal of prior-period presentation adjustment | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, September 26, 2026 | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 6 |
| Series A-1 Shares | Series A-1 Amount | Series S-1 Shares | Series S-1 Amount | Series B Shares | Series B Amount | Series I Shares | Series I Amount | Series M Shares | Series M Amount | Series Q Shares | Series Q Amount | Series V Shares | Series V Amount | Common Stock Shares | Common Stock Amount | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income | Noncontrolling Interest | Total Stockholders Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Series A-1 Shares | Series A-1 Amount | Series S-1 Shares | Series S-1 Amount | Series B Shares | Series B Amount | Series I Shares | Series I Amount | Series M Shares | Series M Amount | Series Q Shares | Series Q Amount | Series V Shares | Series V Amount | Common Stock Shares | Common Stock Amount | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income | Noncontrolling Interest | Total Stockholders’ Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, December 28, 2024 | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for consulting agreement | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for warrants exercised | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for Series V convertible stock converted | — | — | — | — | — | — | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency adjustment | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, March 29, 2025 | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Series A-1 adjustment | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of Series A-1 Preferred | ( | ) | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ALT5 Sigma Corp common stock issued for RSU’s granted | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ALT5 Sigma Corp common stock issued for note payable obligations | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ALT5 Sigma Corp common stock issued for consulting agreement | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ALT5 Sigma Corp common stock issued for Mswipe acquisition | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ALT5 Sigma Corp common stock warrants for Mswipe acquisition | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alyea common stock warrants for Mswipe acquisition | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for Series Q convertible stock converted | — | — | — | — | — | ( | ) | ( | ) | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ALT5 Sigma Corp common stock issued for professional services | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency adjustment | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 28, 2025 | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for Series M conversion | — | — | — | — | ( | ) | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for equity raise | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for RSU’s granted | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for prefunded warrants | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock for warrants exercised | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for notes payable obligations | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Payment of placement fees for equity raise | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income and foreign currency adjustment | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, September 27, 2025 | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 7 |
Note 1: Background
The accompanying consolidated financial statements include the accounts of AI Financial Corporation, a Nevada corporation, and its subsidiaries (collectively, the “Company” or “AIFC”). Effective April 28, 2026, the Company changed its name to “AI Financial Corporation” from “Alt5 Sigma Corporation”. The Company also changed its Nasdaq common stock symbol to “AIFC” from “ALTS.” Previously, effective July 15, 2024, the Company had changed its corporate name to “ALT5 Sigma Corporation” from “JanOne Inc.” and also changed its Nasdaq common stock ticker symbol to “ALTS” from “JAN”. In each instance, the corporate name changes were effected through a parent/subsidiary short-form merger of Company’s wholly-owned Nevada subsidiary formed solely for the purpose of effectuating the name change, whereby that “name change subsidiary” subsidiary merged with and into the Company, with the Company being the surviving entity, albeit with its new name.
The
Company had
On July 29, 2026, the Company agreed to sell ALT5 Sigma Canada, Inc. (“ALT5 Canada”), an indirect wholly owned subsidiary. The transaction closed on August 3, 2026. The results of ALT5 Canada are presented within discontinued operations in the accompanying consolidated financial statements.
Fintech
On May 15, 2024, the Company acquired ALT5 Sigma, Inc. (“ALT5 Subsidiary”). ALT5 Subsidiary is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Subsidiary, through its respective subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime.” ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and/or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency (US Dollars, Canadian Dollars, Euros, and British Pounds Sterling) automatically or to receive their payment in digital assets (see Note 3). The principal subsidiary of the Alt 5 Subsidiary, ALT5 Canada, was sold on August 3, 2026 (see Note 4).
On May 9, 2025, the Company acquired Fortress II Holdings Ltd. d/b/a Mswipe. Mswipe is a next-generation payment solutions provider offering multi-currency, fiat payment card services, along with crypto-enabled capabilities through its existing integration with the ALT5 Subsidiary platform. Its suite of physical and virtual cards, available on both the Visa® and Mastercard® networks, allows users to seamlessly spend traditional and digital currencies worldwide (see Note 3).
Biotechnology
During
September 2019, the Company, through its biotechnology segment, broadened its business perspectives to become a pharmaceutical
company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive
pain-relieving properties. Effective December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability
company (“STLLC”), and its product, a patent-pending, novel formulation of low-dose naltrexone (“JAN123”).
The product is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic
pain generally affecting the arms or legs. At present, there are no truly effective treatments for CRPS. Because of the relatively
small number of patients afflicted with CRPS, the FDA has granted Orphan Drug Designation for any product approved for treatment of
CRPS. This designation will provide the Company with tax credits for its clinical trials, exemption of user fees, and the potential
of
Corporate and Other
Our Corporate and Other segment consists of WLFI assets, including any additions, redemptions, or mark-to-market changes in value, which are recorded within the Company’s Corporate and Other segment.
| 8 |
The
WLFI treasury program was initiated on August 12, 2025, with purchases executed in
| 1. | Tranche 1: | |
| 2. | Tranche 2: |
The
original purchase agreements imposed contractual transfer restrictions on
In connection with the WLFI treasury program, the Company entered into lock-up agreements restricting certain equity issuances. Pursuant to the Purchase Agreements, the Company agreed not to issue, or enter into any agreement to issue, shares of Common Stock or Common Stock equivalents, or file any registration statement or amendment thereto, for a period of 30 days following the closing date of the Offerings, subject to customary exceptions including issuances under the ATM Sales Agreement.
In addition, each of the Company’s directors and executive officers is subject to a lock-up agreement prohibiting the sale, pledge, or other transfer or disposition of 50% of their shares of Common Stock, or securities convertible into or exchangeable for Common Stock, for a period of 90 days following the closing date, with the remaining 50% subject to the same restrictions until the later of 90 days following the closing date or the date Stockholder Approval was obtained. Transfers for bona fide estate or tax planning purposes are permitted, provided the transferee agrees to be bound by the same lock-up terms.
WLFI
is considered a related party to the Company by virtue of the following relationships. Zachary Witkoff, the Chairman of the Company’s
Board of Directors, is a Co-Founder and Chief Executive Officer of WLFI. Zachary Folkman, a member of the Company’s Board of Directors,
is also a Co-Founder of WLFI. In addition, WLFI is the record owner of shares of the Company’s Common Stock and has contractual rights to
pre-funded warrants to purchase up to
All acquisitions of WLFI tokens were executed through on-chain transactions and direct Token Purchase Agreements with the WLFI Foundation. The Company did not hold any WLFI tokens prior to August 12, 2025.
Our Corporate and Other segment consists of certain corporate general and administrative costs.
The Company reports on a 52- or 53-week fiscal year. The Company’s 2025 fiscal year (“2025”) ended on December 27, 2025, and the current fiscal year (“2026”) will end on December 26, 2026.
Liquidity Considerations
The
Company incurred a net loss from continuing operations of approximately $
The
Company holds
The Company’s ability to fund operations and satisfy obligations depends on operating cash flows, available financing and the realization of assets, including WLFI holdings subject to applicable contractual conditions.
Note 2: Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, these financial statements do not include all of the information and notes required for complete financial statements prepared in conformity with U.S. GAAP. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. However, the Company’s results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the consolidated financial statements and notes thereto included in our Form 10-K for the fiscal year ended December 27, 2025.
| 9 |
Principles of Consolidation
The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Financial Statement Reclassification
Certain prior-period amounts have been reclassified to conform to the current period presentation. These reclassifications relate primarily to the presentation of the Biotechnology segment and ALT5 Canada as discontinued operations.
Use of Estimates
The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumption that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Significant estimates made in connection with the accompanying consolidated financial statements include the fair value in connection with the Series S convertible preferred stock issued in the December 28, 2022 acquisition of STLLC, valuation allowance against deferred tax assets, and estimated useful lives for intangible assets.
Financial Instruments
Financial instruments consist primarily of cash, trade and other receivables, and obligations under accounts payable, accrued expenses and notes payable. The carrying amounts of trade and other receivables, accounts payable, accrued expenses and short-term notes payable approximate fair value because of the short maturity of these instruments. The fair value of the long-term debt is calculated based on interest rates available for debt with terms and maturities similar to the Company’s existing debt arrangements, unless quoted market prices were available (Level 2 inputs). The carrying amounts of long-term debt at September 26, 2026 and December 27, 2025 approximate fair value.
Cryptocurrency Assets
The
Company’s cryptocurrency assets consist of World Liberty Financial (“WLFI”) tokens, a scarce, governance-enabled
digital asset with long-term capital preservation and appreciation potential, inflation-hedging characteristics, and embedded
productivity through protocol participation and revenue-sharing mechanisms. With a fixed maximum supply of
Cryptocurrency assets acquired are initially recorded at cost, which represents the cash, cash equivalents, or other financial assets paid to acquire the asset, including transaction fees. Cryptocurrency assets are subsequently measured in accordance with ASC 350-60, Intangibles—Goodwill and Other—Accounting for and Disclosure of Cryptocurrency Assets, at fair value in the statement of financial position with unrealized gains and losses resulting from changes in fair value recognized in net income. The Company determines and records at each reporting period the fair value of its cryptocurrency assets in accordance with ASC 820, Fair Value Measurement, based on quoted (unadjusted) prices. Changes in the fair value are recognized in net income within “Unrealized gain on crypto assets”, while realized gains and losses from the derecognition of crypto assets are included in “Realized gain on crypto assets, net” in the Company’s condensed consolidated statements of operations. Purchases and redemptions of cryptocurrency assets are reflected as cash flows from investing activities in the consolidated statements of cash flows.
Digital Assets and other Receivables
Digital
assets and other receivables are the Company’s digital assets and its customer prepayments in the form of digital assets. The
Company held all digital assets in secure non-custodial wallets through the wallet services from Fireblocks and Utila. As of September 26, 2026,
and December 27, 2025, the outstanding balances of digital assets and other receivables was
and approximately $
Digital Assets and other Payables
Digital
assets and other payables are liabilities that represent the Company’s obligation to deliver the settlement of transactions in
the form of digital assets and or cash. The Company safeguards these digital assets and/or cash for customers and is obligated to safeguard
them from loss, theft, or other misuse. The Company recognizes digital assets and other payables, on initial recognition and at each
reporting date, at fair value of the digital assets. Any loss, theft, or other misuse would impact the measurement of digital assets
and other payables. As of September 26, 2026, the outstanding balance of digital assets and other payables was nil. As of December 27,
2025, the outstanding balance of digital assets and other payables was approximately $
| 10 |
Revenue Recognition
Revenue recognition applies to the Company’s Fintech segment only, as the Company’s Biotech segment has not recognized revenue to date. Revenue is recognized under Topic 606 in a manner that reasonably reflects the delivery of its services and products to customers in return for expected consideration and includes the following elements:
| 1. | Executed contracts with the Company’s customers that it believes are legally enforceable; |
| 2. | Identification of performance obligations in the respective contract; |
| 3. | Determination of the transaction price for each performance obligation in the respective contract; |
| 4. | Allocation of the transaction price to each performance obligation; and |
| 5. | Recognition of revenue only when the Company satisfies each performance obligation. |
These five elements, as applied to each of the Company’s revenue category, are summarized below:
| 1. | Product sales – revenue is recognized at the time of sale of equipment to the customer. |
| 2. | Service sales – revenue is recognized based on when the service has been provided to the customer. |
The Company’s service is comprised of a single performance obligation to buy and sell or convert digital assets to currencies. That is, the Company is the counter-party to all transactions between customers and liquidity providers and presents revenue for the fees earned on a net basis.
The Company is acting as principal in all transactions, and control the digital assets being provided before it is transferred to the buyer, and has risk related to the digital assets, and is responsible for the fulfillment of the digital asset transactions. The Company sets the price for the digital assets by aggregating prices from several liquidity providers and displays them on the Company’s platform. As a result, the Company acts as a price discovery service and acts as a principal facilitating the ability for a customer to purchase or sell digital assets.
The Company considers its performance obligation satisfied, and recognizes revenue, at the point in time that the transaction is processed. Contracts with customers are usually open-ended and can be terminated by either party without a termination penalty. Therefore, contracts are defined at the transaction level and do not extend beyond the service already provided.
The Company charges a fee at the transaction level. The transaction price, represented by the trading fee, is calculated based on volume and varies depending on payment type and the value of the transaction. Digital asset purchases or sale transactions executed by a customer on the Company’s platform is based on tiered pricing that is driven primarily by transaction volume processed for a specific historical period. The Company has concluded that this volume-based pricing approach does not constitute a future material right since the discount is within a range typically offered to a class of customers with similar volume. The transaction fee is collected from the customer at the time the transaction is executed. In certain instances, the transaction fee can be collected in digital assets, with revenue measured based on the amount of digital assets received and the fair value of the digital assets at the time of the transaction. The Company also marks up or down the digital asset prices and earns revenue from the spread between the buying and selling price. The Company also earns a fee from transfers of currencies and or digital assets. The transfer fees are nominal and are set to offset the fees associated with banking and/or blockchain mining fees.
The Company receives consideration in the form of digital assets as payment for commissions and other fees and utilizes these assets as part of its working capital. In accordance with ASC 606, the fair value of digital assets received is measured based on quoted prices in active markets on the date control of the related goods or services transfers to the customer. Subsequent to initial recognition, the Company measures digital assets at fair value using quoted prices obtained from active, highly liquid exchanges that the Company has determined to be its principal market. Because these valuations are based on unadjusted quoted prices for identical assets in active markets, the fair value measurements are classified within Level 1 of the fair value hierarchy. The Company presents these assets within other current assets on its consolidated balance sheets.
| 11 |
The Company from time to time grants restricted stock units, warrants, and stock options to employees, non-employees, and Company executives and directors. Such awards are valued based on the grant date fair-value of the instruments. The value of each award is amortized on a straight-line basis over the vesting period.
Recently Issued Accounting Pronouncements
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and may be adopted on a prospective or retrospective basis. The Company adopted this pronouncement effective with its fiscal year ending December 27, 2025.
Note 3: Mergers and Acquisitions
Block Street
On
April 20, 2026, the Company entered into, a Stock Exchange Agreement (the “SEA”) with the four Stockholders’ of
Block Street Corp., a Nevada corporation (“Block Street”), pursuant to which the Company acquired
The Company evaluated the acquired set under ASC 805 and concluded that it did not meet the definition of a business. Accordingly, the transaction was accounted for as an asset acquisition under ASC 805-50 rather than as a business combination.
The
purchase price for this transaction consisted of shares of the Company’s common stock issued at closing, valued at approximately
$
The
fair value of the purchase price components outlined above was $
Schedule of Business Acquisition
| ALT5 Common stock | $ | |||
| Total purchase price | $ |
The table below outlines the purchase price allocation of the purchase for Block Street to the acquired identifiable intangible assets (in $000’s):
Schedule of Business Acquisition
| Total purchase price | $ | |||
| Total intangible assets acquired | $ |
Mswipe
Effective on May 9, 2025, the Company and our indirect, wholly-owned second-tier Canadian subsidiary entered into an agreement to purchase all of the outstanding capital stock of Fortress II Holdings Ltd. d/b/a Mswipe, an entity that, through its subsidiaries, offers multi-currency, fiat- and crypto-enabled payment card services of Mswipe. The company conducts business under the name Mswipe. Through a suite of physical and virtual cards that are available on both the Visa® and Mastercard® networks, the acquired operations enable users to seamlessly spend traditional and digital currencies across the globe. The platform is built with robust compliance frameworks, advanced security protocols, and real-time exchange capabilities, which allow for fast, secure, and borderless transactions. This is a B2B solution, which, when combined with our other product offerings, bridges the gap between the crypto economy and traditional financial systems—while ensuring regulatory alignment, interoperability with existing payment networks, and a seamless user experience for institutional partners and their end-users.
| 12 |
The
purchase price for this transaction consisted of our (i) issuing
million restricted shares of our common stock to the
The
fair value of the purchase price components outlined above was $
Schedule of Business Acquisition
| ALT5 Common stock | $ | |||
| Common stock warrants | ||||
| Seller notes | ||||
| Drew Common Stock | ||||
| Total purchase price | $ |
Under
the preliminary purchase price allocation, the Company recognized goodwill of approximately $
Schedule of Assets Liabilities Assumed Goodwill
| Total purchase price | $ | |||
| Accounts payable | ||||
| Deferred taxes | ||||
| Total liabilities assumed | ||||
| Total consideration | ||||
| Cash | ||||
| Accounts receivable | ||||
| Property and equipment | ||||
| Intangible assets | ||||
| Customer relationships | ||||
| Trade names | ||||
| Developed technology | ||||
| Subtotal intangible assets | ||||
| Other | ||||
| Total assets acquired | ||||
| Total goodwill |
Proforma Information
The table below presents selected proforma information for the Company for the 13 and 39 weeks ended September 27, 2025, assuming that the acquisition had occurred on December 31, 2023 (the beginning of the Company’s 2024 fiscal year), pursuant to ASC 805-10-50. This proforma information does not purport to represent what the actual results of operations of the Company would have been had the acquisition occurred on that date, nor does it purport to predict the results of operations for future periods (in $000’s).
Schedule of Proforma Information
| As Reported | Adjustments | Proforma | ||||||||||||||
AI Financial Corporation Unaudited 13 weeks ended September 27, 2025 | Mswipe Unaudited 13 weeks ended September 27, 2025 | Adjustments(1) | AI Financial Corporation for the 13 weeks ended September 27, 2025 | |||||||||||||
| Net revenue | $ | $ | $ | |||||||||||||
| Net income | $ | $ | $ | ( | ) | $ | ||||||||||
| Earnings per basic common share | $ | $ | ||||||||||||||
| Earnings per basic diluted share | $ | $ | ||||||||||||||
| 13 |
| As Reported | Adjustments | Proforma | ||||||||||||||
AI Financial Corporation Unaudited 39 weeks ended September 27, 2025 | Mswipe Unaudited 39 weeks ended September 27, 2025 | Adjustments(1) | AI Financial Corporation for the 39 weeks ended September 27, 2025 | |||||||||||||
| Net revenue | $ | $ | $ | |||||||||||||
| Net income | $ | $ | ( | ) | $ | ( | ) | $ | ||||||||
| Earnings per basic common share | $ | $ | ||||||||||||||
| Earnings per basic diluted share | $ | $ | ||||||||||||||
| (1) |
● Amortization expense of definite-lived intangible assets has been adjusted based on the preliminary fair value at the acquisition date.
Note 4: Discontinued Operations
As of December 27, 2025, the Company has characterized its Biotechnology segment as a discontinued operation on its financial statements, as follows: on May 21, 2025, the Company announced the planned formal separation of its healthcare assets, known as Drew, and noted that the scope and method of a partial or full disposition, whatever the methodology, would be determined and announced at a later date. On July 29, 2026, the Company agreed to sell ALT5 Canada; the sale closed on August 3, 2026. Accordingly, the operations of the Alt5 Canada have also been included in discontinued operations as of December 27, 2025.
The comparative December 27, 2025 balances have been reclassified to include ALT5 Canada with Biotechnology in discontinued operations. The reclassification changes the location of assets and liabilities but does not change total assets, total liabilities, mezzanine equity or stockholders’ equity. The following table presents the assets and liabilities of discontinued operations (in $000s).
Schedule Of Discontinued Operations
| September 26, 2026 | December 27, 2025 | |||||||
| Assets from discontinued operations | ||||||||
| Cash and cash equivalents | ||||||||
| Trade and other receivables, net | ||||||||
| Digital assets receivable | ||||||||
| Prepaid expenses and other current assets | $ | $ | ||||||
| Total current assets from discontinued operations | ||||||||
| Property and equipment, net 1 | ||||||||
| Intangible assets, net 2 | ||||||||
| Deferred income taxes | ||||||||
| Goodwill, right-of-use assets and other assets | ||||||||
| Total other assets from discontinued operations | ||||||||
| Total assets from discontinued operations | $ | $ | ||||||
| Liabilities from discontinued operations | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued liabilities - other 3 | ||||||||
| Digital assets payable | ||||||||
| Convertible debentures | ||||||||
| Current operating lease liabilities | ||||||||
| Total current liabilities from discontinued operations | ||||||||
| Total noncurrent liabilities from discontinued operations | ||||||||
| Total liabilities from discontinued operations | $ | $ | ||||||
| 1 |
| September 26, 2026 | December 27, 2025 | |||||||
| Projects under construction | $ | $ | ||||||
| Property and equipment | ||||||||
| Less accumulated depreciation | ||||||||
| Total property and equipment, net, from discontinued operations | $ | $ | ||||||
| 14 |
| 2 | The Company’s intangible assets consisted of the following (in $000s): |
| September 26, 2026 | December 27, 2025 | |||||||
| Soin intangible | $ | $ | ||||||
| Intangible assets | ||||||||
| Less accumulated amortization | ( | ) | ( | ) | ||||
| Soin intangible assets, net | ||||||||
| ALT5 Canada intangible assets, net | ||||||||
| Total intangible assets | $ | $ | ||||||
Biotechnology
was approximately $
Soin Intangible Assets
Effective
as of December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (“STLLC”), and
its product, a patent-pending, novel formulation of low-dose naltrexone. The assets acquired by the Company consist of 1)
| 3 | The Company’s accrued liabilities consisted of the following (in $000s): |
| September 26, 2026 | December 27, 2025 | |||||||
| Due to Dr. Soin | $ | $ | ||||||
| ALT5 Canada accrued liabilities | $ | $ | ||||||
| Total accrued expenses | $ | $ | ||||||
The results of ALT5 Canada and the Biotechnology business are presented within discontinued operations for all periods shown. The following table presents the thirteen- and thirty-nine-week results for September 26, 2026, and September 27, 2025 (in $000s). The comparative reclassification does not change consolidated net income.
| 13 Weeks Ended | 39 weeks Ended | |||||||||||||||
| September 26, 2026 | September 27, 2025 | September 26, 2026 | September 27, 2025 | |||||||||||||
| Revenues | $ | $ | $ | $ | ||||||||||||
| Cost of revenues | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Operating expenses from discontinued operations: | ||||||||||||||||
| Selling, general and administrative expenses | ( | ) | ||||||||||||||
| Total operating expenses from discontinued operations | ( | ) | ||||||||||||||
| Operating income (loss) from discontinued operations | ( | ) | ( | ) | ||||||||||||
| Other income (expense) from discontinued operations | ( | ) | ( | ) | ( | ) | ||||||||||
| Total other income (loss), net | ( | ) | $ | ( | ) | $ | ( | ) | ||||||||
| Loss before provision for income taxes from discontinued operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Income tax benefit (provision) | ( | ) | ( | ) | ||||||||||||
| Net income (loss) from discontinued operations | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||
| 15 |
In accordance with the provisions of ASC 360-10 and ASC 205-20, the Company has separately reported the cash flow activity of the discontinued operations in the consolidated statements of cash flows. The cash flow activity from discontinued operations for the 39 weeks ended September 26, 2026 and September 27, 2025, has been reflected as discontinued operations in the consolidated statements of cash flows and consists of the following (in $000s):
| 39 weeks ended | ||||||||
| September 26, 2026 | September 27, 2025 | |||||||
| DISCONTINUED OPERATING ACTIVITIES: | ||||||||
| Net loss from discontinued operations | $ | ( | ) | $ | ( | ) | ||
| Depreciation and amortization | ||||||||
| Other noncash and working-capital adjustments | ||||||||
| Change in deferred taxes | ||||||||
| Changes in assets and liabilities: | ||||||||
| Prepaids and other current assets | ||||||||
| Accounts payable and accrued expenses | ( | ) | ( | ) | ||||
| Net cash provided by (used in) operating activities from discontinued operations | $ | ( | ) | $ | ||||
| DISCONTINUED INVESTING ACTIVITIES: | ||||||||
| Net cash used in investing activities from discontinued operations | $ | ( | ) | $ | ||||
| DISCONTINUED FINANCING ACTIVITIES: | ||||||||
| Net cash used in financing activities from discontinued operations | $ | $ | ||||||
Cash paid for interest during the
thirty-nine weeks ended September 26, 2026, totaled $
Sale of ALT5 Sigma Canada, Inc.
On
July 29, 2026, the Company and its first tier, wholly -owned subsidiary, Alt 5 Sigma, Inc. (a Delaware corporation referenced in Note
1 as the “ALT5 Subsidiary”), entered into an Acquisition Agreement with Prime Delta Corp., a Delaware corporation (“Prime
Delta”), pursuant to which the Alt 5 Subsidiary sold to Prime Delta all of the issued and outstanding shares of Alt 5 Sigma Canada,
Inc. (“Alt 5 Canada”; referenced in these Notes as our indirect, wholly-owned second tier Canadian subsidiary), through which
the Company conducted its payments business. In exchange, the Company received the following consideration: (i) a four (
The Prime Delta Note is secured by substantially all of the assets of Prime Delta and is guaranteed by certain affiliates of Prime Delta. In connection with the transaction, the Company assigned to Prime Delta the “Alt 5” and “Alt 5 Sigma” trademarks and related rights, agreed to cease use of those names, and agreed to change the names of its subsidiaries whose legal names include “Alt 5” within 90 days following the closing.
Additionally, through counsel for Prime Delta, the Company may offer the holders of its Series B Preferred Stock the opportunity to redeem their shares of Series B Preferred Stock, on a consensual basis, in exchange for their pro rata share of up to shares of Prime Delta Stock, on a one share of Series B Preferred Stock for one share of Prime Delta Stock basis. No such redemption offer has commenced, and no documentation has been prepared or filed, as applicable.
Note 5: Trade and other receivables
The Company’s trade and other receivables as of September 26, 2026 and December 27, 2025, respectively, were as follows (in $000’s):
Schedule of Trade and Other Receivables
| September 26, 2026 | December 27, 2025 | |||||||
| Other receivables | $ | $ | ||||||
| Trade and other receivables, net | $ | $ | ||||||
| 16 |
Note 6: Prepaids and other current assets
Prepaids and other current assets as of September 26, 2026 and December 27, 2025 consist of the following (in $000’s):
Schedule of Other Current Assets
| September 26, 2026 | December 27, 2025 | |||||||
| Prepaid interest | $ | $ | ||||||
| Prepaid insurance | ||||||||
| Prepaid other | ||||||||
| Total prepaid expenses and other current assets | $ | $ | ||||||
Note 7: Property and Equipment
Property and equipment as of September 26, 2026 and December 27, 2025 consist of the following (in $000’s):
Schedule of Property and Equipment
| September 26, 2026 | December 27, 2025 | |||||||
| Furniture and fixtures | $ | $ | ||||||
| Computer equipment | ||||||||
| Property and equipment | ||||||||
| Property and equipment gross | ||||||||
| Accumulated depreciation | ( | ) | ( | ) | ||||
| Total property and equipment, net | $ | $ | ||||||
Note 8: WLFI Treasury Program
The
WLFI treasury program was initiated on August 12, 2025, with purchases executed in
| ● | Tranche 1: | |
| ● | Tranche 2: |
All acquisitions were executed through on-chain transactions and direct Token Purchase Agreements with the WLFI Foundation. The Company did not hold any WLFI tokens prior to August 12, 2025.
The outstanding units, cost basis, and fair value as of September 26, 2026 were as follows (in $000’s, except for units):
Schedule of Outstanding Units, Cost Basis and Fair Value
| Units | Cost Basis | Fair Value | ||||||||||
| Balance, September 26, 2026: | ||||||||||||
| WLFI | $ | $ | ||||||||||
| Total | $ | $ | ||||||||||
The following table presents a reconciliation of WLFI assets to fair value as of September 26, 2026 (in $000’s):
Schedule of Reconciliation of WLFI Assets to Fair Value
| September 26, 2026 | ||||
| Fair value, December 27, 2025 | $ | |||
| Fair value, beginning balance | $ | |||
| Additions | ||||
| Redemptions | ||||
| Fees paid | ||||
| Subtotal | ||||
| Unrealized loss | ||||
| Fair value, September 26, 2026 | $ | |||
| Fair value, ending balance | ||||
During
the 39 weeks ended September 26, 2026, the Company recognized an unrealized loss of approximately $
| 17 |
Concrete Agreement
Alt5 Digital Holdings, Inc. entered into a two-year arrangement with related party Concrete Network Services Ltd. under a Master
Services Agreement and Statement of Work dated July 13, 2026; the relationship is described in Note 21. The Company retains legal
and beneficial title to the delegated WLFI tokens and continues to recognize them at fair value, including $
At September 26, 2026, pledged WLFI assets totaled $
Note 9: Intangible Assets
Intangible assets as of September 26, 2026 and December 27, 2025 consist of the following (in $000’s):
Schedule of Intangible Assets
| September 26, 2026 | December 27, 2025 | |||||||
| Noncompete agreements | $ | $ | ||||||
| Qoden intangible | ||||||||
| Patents and domains | ||||||||
| Trade names | ||||||||
| Customer relationships | ||||||||
| Block Street intangible | ||||||||
| Developed technology | ||||||||
| Intangible assets | ||||||||
| Total intangible assets gross | ||||||||
| Less accumulated amortization | ( | ) | ( | ) | ||||
| Total intangible assets | $ | $ | ||||||
Intangible
amortization expense from continuing operations was approximately $
Block Street
Effective on April 20, 2026, the Company entered into an agreement to purchase all of the outstanding capital stock of Block Street which operates a platform designed to support token issuances aligned with applicable regulatory frameworks and the tokenization of real-world assets. Block Street’s capabilities have not yet been deployed commercially and Block Street has not generated revenues to date. The Company will amortize the intangible assets over a ten (10)-year period when the assets are placed in service (see Note 3).
Mswipe
Effective on May 9, 2025, the Company and our indirect, wholly-owned second tier Canadian subsidiary entered into an agreement to purchase all of the outstanding capital stock of an entity that, through its subsidiaries, offers multi-currency, fiat- and crypto-enabled payment card services (see Note 3).
Qoden Intangible Assets
On November 8, 2024, the Company acquired the Qodex Cryptocurrency Exchange Software platform and other related assets
from Qoden Technologies, LLC, a provider of technology solutions for the blockchain industry. The Company was planning to amortize the
intangible assets over a two
ALT5 Subsidiary Intangible Assets
On May 14, 2024, the Company acquired its ALT5 Subsidiary, which is a fintech company that provides next generation
blockchain-powered technologies to enable a migration to a new global financial paradigm. As part of the acquisition, the Company acquired
trade names, customer relationships, and developed technology, which were originally planned to be amortized over a period of
Note 10: Goodwill
The following table details the Company’s goodwill as of September 26, 2026 and December 27, 2025 (in $000’s):
Schedule of Goodwill
| Fintech | Biotech | Corporate and Other | Total | |||||||||||||
| December 27, 2025 | ||||||||||||||||
| Goodwill disposed of with ALT5 Canada | ( | ) | ( | ) | ||||||||||||
| September 26, 2026 | $ | $ | $ | $ | ||||||||||||
Total
goodwill at December 27, 2025 was $
The
Company accounts for purchased goodwill and intangible assets in accordance with ASC 350, Intangibles—Goodwill and Other. Goodwill
recognized during the 39 weeks ended September 27, 2025 was approximately $
| 18 |
Note 11: Accrued Liabilities
Accrued liabilities as of September 26, 2026 and December 27, 2025 consist of the following (in $000’s):
Schedule of Accrued Liabilities
| September 26, 2026 | December 27, 2025 | |||||||
| Compensation and benefits | $ | $ | ||||||
| Accrued guarantees | ||||||||
| Accrued settlements | ||||||||
| Accrued interest | ||||||||
| Accrued professional fees | ||||||||
| Accrued Qoden payments | ||||||||
| Accrued litigation/legal | ||||||||
| Customer deposits | ||||||||
| Other | ||||||||
| Total accrued expenses | $ | $ | ||||||
Note 12: Debentures
Debentures outstanding as of September 26, 2026, and December 27, 2025, consisted of the following (in $000’s):
Schedule of Debenture Outstanding
| September 26, 2026 | December 27, 2025 | |||||||
| Interest rate of 12%, maturity date of June 30, 2025 | $ | $ | ||||||
| Interest rate of | $ | $ | ||||||
| Total debentures | $ | $ | ||||||
ALT5
Subsidiary issued
During
March 2026,
Note 13: Debt
At
September 26, 2026, the Company had a $
Long-term debt as of September 26, 2026, and December 27, 2025, consisted of the following (in $000’s):
Schedule of Long-Term Debt
| September 26, 2026 | December 27, 2025 | |||||||
| Fixed deposits | $ | $ | ||||||
| WLFI loan | ||||||||
| Unaffiliated third-party | ||||||||
| Seller notes | ||||||||
| Concrete client advance | ||||||||
| Insurance premium financing | ||||||||
| Total notes payable | ||||||||
| Less current portion | ( | ) | ( | ) | ||||
| Total long-term notes payable | $ | $ | ||||||
Fixed Deposits
The
Company entered into Corporate Fixed Deposit Agreements with unaffiliated third parties bearing interest at
WLFI Loan Agreement
On January 29, 2026, we, through our indirect, wholly-owned subsidiary, ALT5 Digital Holdings, Inc. (“ALT5 Digital” or the “Borrower”), entered into a Master Loan and Security Agreement (the “Loan Agreement”) with WLFI. Zachary Witkoff, Chairman of our Board, is the Chief Executive Officer and Co-Founder of WLFI, and Zachary Folkman, a member of our Board, is the Co-Founder of WLFI.
The
Loan Agreement provides for collateralized loans in the aggregate principal amount of $
| 19 |
The Loan Agreement includes customary representations, warranties, covenants, risk disclosures relating to digital asset collateral, and other terms and conditions customary for transactions of this type, including provisions regarding public disclosure, successor and assignment rights, modification and waiver, notices, and interpretation. The governing law for the Loan Agreement and related documents (other than UCC matters) is the law of the State of Delaware, and disputes are subject to binding arbitration administered by the International Centre for Dispute Resolution seated in Miami, Florida.
On
January 29, 2026, the Borrower drew the $
As of March 28, 2026, the Company pledged WLFI, with an additional pledged in the 13 weeks ended September 26, 2026, for a total of WLFI tokens as collateral as of September 26, 2026.
Unaffiliated Third-Party Loans
ICG Note
On
February 7, 2024, the Company amended its outstanding related party promissory obligations (the “ICG Note”) in favor of Isaac
Capital Group LLC (“ICG”) to add a convertibility provision. In accordance with Nasdaq Rules, the per-share conversion price
was set at $, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro
rata distributions. The Company’s board of directors provided its approvals of the amendments on February 7, 2024. On March 6,
2024, ICG entered into a Note Purchase Agreement with an otherwise unaffiliated third party, under which the third party acquired the
ICG Note. The terms and conditions of the ICG Note were not modified in connection with its acquisition by the third party. The principal
amount of the ICG Note on the date of acquisition was approximately $
Big/Small Debentures
On
August 20, 2024, the Company entered into
The
Debentures are unsecured and subordinated to any existing or future debt. The Debentures bear interest at a rate of (i)
The
Big Debenture was issued with an original issue discount (an “OID”) initially of $
The
Small Debentures were issued with an OID initially of $
| 20 |
As
of November 1, 2024, the first of the
The
Big Warrant is exercisable, at an exercise price of $
The
Small Warrant is exercisable, at an exercise price of $
As of November 1, 2024, the contingent second tranche of the Warrants vested.
Except
as disclosed with respect to the final tranche of the Big Warrant, each Investor is required to exercise the initial tranche of each
Warrant within
During
the quarter ended September 27, 2025, one of the two non-affiliated Investors exercised the remainder of the Small Warrant for a total
of shares (see Note 16). During the fourth quarter of the year ended December 28, 2024, the non-affiliated Investor exercised
the Big Warrant for a total of shares of the Company’s common stock, and the other two non-affiliated Investors exercised
the Small Warrant for a total of shares. Additionally, during the fourth quarter of the year ended December 28, 2024, these unaffiliated
third-parties agreed to convert a portion their respective investment into Future Equity Agreements of the Company’s subsidiary,
Drew and, consequently, approximately $
Amendments to Promissory Notes and Warrants
Effective
July 7, 2026, the Company entered into Extension and First Amendment Agreements with the holders of ten promissory notes with an aggregate
principal amount of CAD$
Note 14: Commitments and Contingencies
Litigation
SEC Complaint
On
August 2, 2021, the U.S. Securities and Exchange Commission (“SEC”) filed a civil complaint (the “SEC
Complaint”) in the United States District Court for the District of Nevada naming the Company and one of its executive
officers, Virland Johnson, the Company’s Chief Financial Officer, as defendants (collectively, the “Defendants”).
Pursuant to an agreed-upon Order of the Court, on May 28, 2024, the Company settled its litigation with the SEC. The Company’s
Settlement Agreement provided, in pertinent part: “Without admitting or denying the allegations of the complaint (except as
provided herein in paragraph 12 and except as to personal and subject matter jurisdiction, which [the Company] admits), [the
Company] hereby consents to the entry of the final Judgment in the form attached hereto (the “Final Judgment”) and
incorporated by reference herein, which, among other things: “(a) permanently restrains and enjoins [the Company] from
violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder [15 U.S.C. § 78j(b) and 17 C.F.R.
§§ 240.10b-5]; and (c)[sic] orders [the Company] to pay a civil penalty in the amount of $
| 21 |
Pursuant to a Joint Motion filed by the SEC and Mr.
Johnson, among others, and upon an Amended Final Judgment of the Court, on August 26, 2026, Mr. Johnson’s litigation with the SEC
was settled. Mr. Johnson’s accepted Offer of Settlement provided, in pertinent part: “Solely for the purpose of these proceedings
and any other proceedings brought by or on behalf of the Commission or in which the Commission is a party, and without admitting the findings
contained in the Order, except with respect to the findings contained in paragraph 3 below, which are admitted, consents to the entry
of an Order by the Commission . . .” Paragraph 3 thereof provided, “… the court entered an order permanently enjoining
Johnson, by consent, from future violations of Exchange Act Rule 13b2-2 [17 C.F.R. § 240.13b2-2], as set forth in the judgment entered
in the civil action entitled Securities and Exchange Commission v. Live Ventures, et al., Civil Action Number 2:21-cv-01433-JCM-MDC, in
the United States District Court for the District of Nevada. Johnson was also ordered to pay a $
Sieggreen
In a matter pending in the United States District Court for the District Of Nevada, Case No. 2:21-cv-01517-CDS-EJY, styled as Sieggreen, Individually and On Behalf of All Others Similarly Situated, Plaintiff, v. Live Ventures Incorporated, Jon Isaac, and Virland A. Johnson, Defendants, the Company was added as a defendant on March 6, 2023, and was served on March 23, 2023. Plaintiff has alleged causes of action against the Company for (i) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder and (ii) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rules 10b-5(a) and 10b-5(c) promulgated thereunder. In June 2023 the Company filed a Motion to Dismiss, which the Court granted with leave for Plaintiffs to file a second amended complaint. Plaintiffs filed their Second Amended Complaint on October 31 2024. On December 16, 2024, the Company filed a Motion to Dismiss, which the Court denied. Thereafter, the Company filed an answer to the Second Amended Complaint. The Company strongly disputes and denies all of the allegations contained therein and will continue to defend itself vigorously against the claims.
Main/270
The
Company is a defendant in an action filed on April 11, 2022, in the U.S. District Court Southern District of Ohio, Eastern Division,
styled, Trustees Main/270, LLC, Plaintiff, vs ApplianceSmart, Inc. and JANONE, Inc., Defendant, Case No.: 2:22-cv-01938-ALM-EPD.
In November 2026, the parties reached a settlement agreement in this matter, pursuant to which the Company agreed to pay to the plaintiff
approximately $
Gulf Coast Bank and Trust vs. ALT5 Sigma Corporation, et al.
In
a matter in the United States District Court for the State of Minnesota, Hennepin County, Case No. 27-CV-24-340, styled as Gulf Coast
Bank and Trust Company, Plaintiffs, v ARCA Recycling, Inc., JanOne Inc., and Virland A. Johnson, Defendants; plaintiff sought the
payment of approximately $
Virland Johnson Bankruptcy
On August 14, 2025, the Company received a Summons and Complaint in an Adversary Proceeding (the “Complaint”) filed on August 6, 2025 in connection with the Chapter 7 bankruptcy proceeding titled In re Virland Johnson, No. 2:24-bk-00226-BKM, pending in the United States Bankruptcy Court for the District of Arizona and involving the Company’s former Chief Financial Officer, Virland Johnson. The Complaint alleges that Mr. Johnson had been awarded in October 2023 restricted stock units entitling him to receive shares of the Company’s common stock under the Company’s 2023 Equity Incentive Plan. According to the Complaint, Mr. Johnson did not disclose the existence of the stock award in his January 11, 2024 Chapter 7 bankruptcy petition or accompanying disclosure schedules. The Complaint alleges that the common stock may not have been delivered to Mr. Johnson, may have been assigned by Mr. Johnson to the Company or another unknown assignee, may have been sold by Mr. Johnson, or may even continue to be held by Mr. Johnson. Through the Complaint, the U.S. Trustee seeks to recover the common stock or, if it is no longer available, the equivalent value from the Company on behalf of the bankruptcy estate. On September 30, 2025 the Company filed its Answer to the Complaint and denied the allegations of any wrongdoing by the Company. The Company disputes the allegations concerning the Company and will continue to defend itself vigorously against the claims.
| 22 |
First Capital Consulting, Inc. DBA Trusaic vs. ALT5 Sigma Corporation
In
a matter in the Los Angeles, California Superior Court Case No. 24STCV02261, styled as First Capital Consulting, Inc., Plaintiff v
ALT5 Sigma Corporation, ARCA Recycling, Inc., Customer Connexx LLC; and DOES 3 through 10, inclusive, Defendants; plaintiff was seeking
$
Judgment in Rwanda
ALT5
Sigma Canada, Inc., formerly an indirect wholly-owned subsidiary of the Company, was sold to Prime Delta Corp. on August 3, 2026.
The former subsidiary is the subject of proceedings in Rwanda concerning US$
Other Commitments
On
December 30, 2017, the Company disposed of its retail appliance segment and sold ApplianceSmart to Live Ventures Incorporated
(“Live Ventures”), a related party. In connection with that sale, as of January 1, 2022, the Company accrued an
aggregate amount of future real property lease payments of approximately $
The Company is party from time to time to other ordinary course disputes that we do not believe to be material to our financial condition as of September 26, 2026.
Note 15: Registered Direct Offering
Registered Direct Offering
On or about August 12, 2025, the Company entered into securities purchase agreements (the “Registered Offering Purchase Agreements”) with certain institutional investors, pursuant to which the Company agreed to issue to the Purchasers (as defined therein), in a registered direct offering (the “Registered Offering”), an aggregate of shares of the Company’s common stock, par value $ per share (“Common Stock”), at a purchase price of $ per share.
The
Company intends to use up to $
| 23 |
Private Placement Offering
Also,
on August 12, 2025, the Company consummated transactions resulting from a Securities Purchase Agreement (the “Private
Placement Purchase Agreement” and, together with the Registered Offering Purchase Agreements, the “Purchase
Agreements”), with the Lead Investor, pursuant to which the Company received $
Pursuant
to the Private Placement Purchase Agreement, the Lead Investor was issued Common Stock Purchase Warrants (the “Lead Investor Warrants”)
to purchase up to
The issuance and sale of the PIPE Shares, the PIPE Pre-Funded Warrants, the Lead Investor Warrants, and the Lead Investor Shares (collectively, the “PIPE Securities”) were not registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws. The PIPE Securities were, or will be, as relevant, issued in reliance on the exemption from registration provided by Section 4(a)(2) under the Securities Act and/or Regulation D promulgated thereunder for transactions not involving a public offering. Pursuant to the terms of the Registration Rights Agreement (as defined herein), the Company is required to file a registration statement providing for the resale of the PIPE Securities within 15 days of the closing of the Private Placement. As of the date of this Quarterly Report, the registration statement has not yet been filed.
The
Registered Offering resulted in gross proceeds of $
Pursuant to the Purchase Agreements, the Company has agreed not to issue, enter into any agreement to issue, or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock equivalents, or file any registration statement or any amendment or supplement thereto, for a period of thirty (30) days after the initial registration statement was declared effective, subject to certain customary exceptions, including the use of the Sales Agreement (as defined herein), without the consent of the Purchasers, the Lead Investor, and the Placement Agent.
Placement Agency Agreements
The
Company entered into a Placement Agency Agreement with A.G.P./Alliance Global Partners (the “Placement Agent”), dated August
11, 2025, pursuant to which the Placement Agent acted as the exclusive placement agent for the Company in connection with the Registered
Offering (the “RD Placement Agency Agreement”). Pursuant to the RD Placement Agency Agreement, the Company paid the Placement
Agent a cash fee of
| 24 |
The
Company also entered into a Placement Agency Agreement with the Placement Agent, dated August 11, 2025, pursuant to which the Placement
Agent acted as the exclusive placement agent for the Company in connection with the Private Placement (the “PIPE Placement Agency
Agreement”). Pursuant to the PIPE Placement Agency Agreement, the Company paid the Placement Agent (or its designees) a cash fee
of (i) $
The issuance of the Placement Agent Warrants and the shares of Common Stock underlying the Placement Agent Warrants (the “Placement Agent Warrant Shares”) will not be registered under the Securities Act or any state securities laws. The Placement Agent Warrant Shares will be issued in reliance on the exemption from registration provided by Section 4(a)(2) under the Securities Act and/or Regulation D promulgated thereunder for transactions not involving a public offering.
The Placement Agency Agreement contains customary representations, warranties, and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties, and termination provisions.
On
December 30, 2025, the Company entered into an agreement (the “Placement Agent Subsequent Agreement”) with the Placement
Agent that modified certain of the terms of the Placement Agent Agreements. The parties agreed, subject to certain limitations, to
extend the Placement Agent’s irrevocable right of first refusal to act as sole investment banker, sole book-runner, sole sales
agent, and/or sole placement agent, at its sole discretion, for the Company’s future public and private equity and debt
offering, including all equity linked financings, through December 31, 2026, on terms customary to the Placement Agent. The fee tail
period, as provided in the Placement Agent Agreements, was also extended from August 12, 2026, through December 31, 2026. In
connection with such extensions, the Placement Agent (i) paid the Company the sum of one million dollars and (ii) agreed that, once
it has received
Registration Rights Agreement
On
or about August 11, 2025, the Company and the Lead Investor entered into a Registration Rights Agreement requiring a resale
registration statement within 15 days after closing and effectiveness within the contractual deadline. The resale registration
statement has not been filed. Section 2(d) provides liquidated damages of $
Lock-Up Agreements
Pursuant to the Purchase Agreements, the Company will not issue, enter into any agreement to issue, or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock equivalents, or file any registration statement or any amendment or supplement thereto, for a period of 30 days after the Effective Date, subject to certain customary exceptions, including the use of the Sales Agreement (as defined herein), without the consent of the Purchasers, the Lead Investor and the Placement Agent.
| 25 |
In
addition, each of the Company’s directors and executive officers are subject to a lock-up agreement, which prohibits them from
offering for sale, pledging, announcing the intention to sell, selling, contracting to sell, granting any option, right or warrant to
purchase, or otherwise transferring or disposing of,
Common Stock: Our Articles of Incorporation authorize billion shares of common stock that may be issued from time to time having such rights, powers, preferences and designations as the Board of Directors may determine. During the 13 weeks ended September 26, 2026, and September 27, 2025, shares of common stock were issued in lieu of professional services.
During the 39 weeks ending September 26, 2026, the Company issued shares of its common stock for the acquisition of Block Street.
During
the 39 weeks ending September 27, 2025, the Company issued shares of its common stock to one individual under the Company’s
2023 Equity Incentive Plan. The aggregate value of the shares at issuance was approximately $
During the 39 weeks ending September 27, 2025, the Company issued shares of its common stock to a non-affiliated third-party in exchange for brokerage services rendered.
During
the 39 weeks ending September 27, 2025, the Company issued an aggregate of restricted stock units to Tony Isaac, the Company’s
President. of the restricted stock units were issued from the Company’s 2024 Plan and were issued from the Company’s
2023 Plan. The aggregate value of the shares at issuance was approximately $
During
the 39 weeks ending September 27, 2025, pursuant to the terms and conditions of a related party promissory note, the Company converted
approximately $
During
the quarter ended September 27, 2025, pursuant to the terms and conditions of a related party promissory note, the Company converted
approximately $
On
May 15, 2025, pursuant to the terms and conditions of a promissory note, the Company converted approximately $
On May 9, 2025, the Company acquired Mswipe. As consideration under the acquisition, the Company issued shares of its common stock to the sellers of Mswipe (see Note 3).
On May 2, 2025, the Company entered into a licensing agreement with a non-affiliated third party, pursuant to which the third party will provide software licensing and support to the Company. In connection with the agreement, the Company issued to the third party shares of its common stock.
During the year ended December 27, 2025, the Company issued shares of its common stock related to the exercise of warrants under the Small Debenture (see Note 13).
On May 4, 2024, the Company entered into an Asset Purchase Agreement for the purchase of specified assets of an unaffiliated third party. In connection with this transaction, the Company tendered shares of the Company’s Series V Convertible Preferred Stock. The conversion ratio of the Series V Convertible Preferred Stock is 1:120, meaning every one share of Series V Convertible Preferred Stock, if and when converted into shares of Common Stock, shall convert into shares of Common Stock. On March 12, 2025, the unaffiliated third-party exercised all tendered shares of Series V Convertible Preferred Stock into shares of the Company’s common stock.
On January 15, 2025, the Company entered into a six-month consulting agreement with a non-affiliated third-party, pursuant to which the third-party will provide a variety of corporate advisory services related to investment banking matters to the Company. In connection with the agreement, on January 15, 2025, the Company issued to the third-party shares of its common stock.
As of September 26, 2026, and December 27, 2025, there were and , respectively, of common stock issued and and shares, respectively, of common stock outstanding, net of shares held in Treasury of as of September 26, 2026.
| 26 |
Equity Offerings: The Company’s 2024 Plan, which was adopted by the Board in November 2024 and approved by the Stockholders’ at the 2024 annual meeting of stockholders, replaces the 2023 Plan, which replaced the 2016 Plan, which replaced the 2011 Plan. Under the 2024 Plan, the maximum aggregate number of shares, which may be subject to or delivered under Awards granted under the Plan is shares. Awards may be in the form of a Stock Award, Option, Stock Appreciation Right, Stock Unit, or Other Stock-based Award granted in accordance with the terms of the respective Plan. During the 13 weeks ended September 27, 2026, there were no grants under the 2024 Plan.
The Company’s 2023 Plan, which was adopted by the Board in August 2023 and approved by the Stockholders’ at the 2023 Annual Meeting of Stockholders, replaces the 2016 Plan, which replaced the 2011 Plan. Under the 2023 Plan, the maximum aggregate number of shares, which may be subject to or delivered under Awards granted under the Plan is two million () shares. Awards may be in the form of a Stock Award, Option, Stock Appreciation Right, Stock Unit, or Other Stock-based Award granted in accordance with the terms of the respective Plan. During the 39 weeks ended September 26, 2026, and September 27, 2025, the Company recognized $ and $ in share-based compensation expense related to the RSU’s that were awarded and immediately vested.
The Company’s 2016 Plan authorizes the granting of awards in any of the following forms: (i) incentive stock options, (ii) nonqualified stock options, (iii) restricted stock awards, and (iv) restricted stock units, and expires on the earlier of October 28, 2026, or the date that all shares reserved under the 2016 Plan are issued or no longer available. On November 4, 2020, the Company amended the 2016 Plan to increase the issuance of common shares from to . The vesting period is determined by the Board of Directors at the time of the stock option grant. As of September 26, 2026, and December 27, 2025, options were outstanding under the 2016 Plan.
The Company’s 2011 Plan authorizes the granting of awards in any of the following forms: (i) stock options, (ii) stock appreciation rights, and (iii) other share-based awards, including but not limited to, restricted stock, restricted stock units or performance shares, and expired on the earlier of May 12, 2021, or the date that all shares reserved under the 2011 Plan are issued or no longer available. As of September 26, 2026, and December 27, 2025, were outstanding under the 2011 Plan. No additional awards will be granted under the 2011 Plan.
The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. There were no stock options granted during the 13 weeks ended September 26, 2026.
Schedule of Additional Information Relating to All Outstanding Stock Options
Options Outstanding | Weighted Average Exercise Price | Aggregate Intrinsic Value | Weighted Average Remaining Contractual Life | |||||||||||||
| Outstanding at December 27, 2025 | $ | | $ | |||||||||||||
| Outstanding at March 28, 2026 | $ | $ | ||||||||||||||
| Outstanding at June 27, 2026 | $ | $ | ||||||||||||||
| Outstanding at September 26, 2026 | $ | $ | ||||||||||||||
| Exercisable at September 26, 2026 | $ | $ | ||||||||||||||
The Company recognized $ and $ in share-based compensation expense related to restricted stock units for the 13 weeks ended September 26, 2026, and September 27, 2025, respectively, and $ and $ for the 39 weeks ended September 26, 2026, and September 27, 2025, respectively.
As of September 26, 2026, the Company had unrecognized share-based compensation expense associated with equity awards.
Series I Convertible Preferred Stock
Shares
of Series I Preferred Stock are convertible into the Company’s common shares at a ratio of
| 27 |
Series Q Convertible Preferred Stock
Shares
of Series Q Preferred Stock are convertible into the Company’s common shares at a ratio of
Series S Preferred Stock
On
December 28, 2022, the Company acquired Soin Therapeutics LLC, by way of a triangular merger. In connection with this transaction, with
a potential value of up to $
Series V Convertible Preferred Stock
Shares
of Series V Preferred Stock are convertible into the Company’s common shares at a ratio of
Note 17: Mezzanine Equity
During
the year ended December 28, 2024, the Company reclassified approximately $
Net
income (loss) per share is calculated using the weighted average number of common shares outstanding during the applicable period.
The
Schedule of Computation of Basic and Diluted Net Loss Per Share
| September 26, 2026 | September 27, 2025 | September 26, 2026 | September 27, 2025 | |||||||||||||
| For the Thirteen Weeks Ended | For the Thirty-Nine Weeks Ended | |||||||||||||||
| September 26, 2026 | September 27, 2025 | September 26, 2026 | September 27, 2025 | |||||||||||||
| Net income (loss) from continuing operations | ( | ) | ( | ) | ||||||||||||
| Net income (loss) from discontinued operations | ( | ) | ( | ) | ( | ) | ||||||||||
| Net income (loss) | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Net income (loss) per share: | ||||||||||||||||
| Net income (loss) per share from continuing operations, basic | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Net income (loss) per share from continuing operations, diluted | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Net income (loss) per share from discontinued operations, basic | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||
| Net income (loss) per share from discontinued operations, diluted | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||
| Net income (loss) per share, basic | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Net income (loss) per share, diluted | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic | ||||||||||||||||
| Diluted | ||||||||||||||||
| 28 |
Potential common shares are excluded from diluted earnings per share when their effect would be antidilutive.
Note 19: Income Taxes
The
Company recorded income tax benefits from continuing operations of approximately $
Note 20: Segment Information
The
following
The following tables present revenue, cost of revenue, gross profit, selling, general and administrative expenses and operating income (loss) for the thirteen and thirty-nine weeks ended September 26, 2026, and September 27, 2025 (in thousands).
Schedule of Segment Information
| Fintech | Corporate and Other | Discontinued operations | Total | Fintech | Corporate and Other | Discontinued operations | Total | |||||||||||||||||||||||||
| 13 Weeks Ended September 26, 2026 | 13 Weeks Ended September 27, 2025 | |||||||||||||||||||||||||||||||
| Fintech | Corporate and Other | Discontinued operations | Total | Fintech | Corporate and Other | Discontinued operations | Total | |||||||||||||||||||||||||
| Revenue | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||
| Cost of revenue | ||||||||||||||||||||||||||||||||
| Gross profit | ||||||||||||||||||||||||||||||||
| Selling, general and administrative expenses | ( | ) | ||||||||||||||||||||||||||||||
| Operating income (loss) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||
| Fintech | Corporate and Other | Discontinued operations | Total | Fintech | Corporate and Other | Discontinued operations | Total | |||||||||||||||||||||||||
| 39 weeks Ended September26, 2026 | 39 weeks Ended September 27, 2025 | |||||||||||||||||||||||||||||||
| Fintech | Corporate and Other | Discontinued operations | Total | Fintech | Corporate and Other | Discontinued operations | Total | |||||||||||||||||||||||||
| Revenue | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||
| Cost of revenue | ||||||||||||||||||||||||||||||||
| Gross profit | ||||||||||||||||||||||||||||||||
| Selling, general and administrative expenses | ||||||||||||||||||||||||||||||||
| Operating income (loss) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||
Note 21: Related Parties
Shared Services
Tony
Isaac, the Company’s President, is the father of Jon Isaac, President and Chief Executive Officer of Live Ventures and managing
member of Isaac Capital Group LLC (“ICG”). Tony Isaac is a member of the Board of Directors of Live Ventures. The Company
also shares certain executive, accounting and legal services with Live Ventures. The total services shared were approximately $
Concrete Network Services Ltd. is owned by the chief technology officer of World Liberty Financial, whose chief executive officer is the chairman of the Company’s board. The pledged collateral, advance, expense, yield and loss-sharing commitments under this related-party arrangement are described in Note 8.
Note 22: Subsequent Events
The subsequent events described below reflect information available through November 10, 2026.
Fixed Deposits
Approximately $
Margin call
Subsequent to September 26, 2026, the Company received a margin call in connection with the Concrete arrangement described in Note 8.
On November 5, 2026 the Company transferred a total of WLFI
tokens, with a fair market value of $
| 29 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to provide a reader of our financial statements with a narrative from the perspective of our management on our financial condition, results of operations, liquidity and certain other factors that may affect our future results. Dollars stated in thousands, except per–share amounts.
Forward-Looking and Cautionary Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of Exchange Act, which involve risks and uncertainties. You can identify forward-looking statements because they contain words such as ‘‘believes,’’ ‘‘expects,’’ ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘seeks,’’ ‘‘approximately,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘estimates’’ or ‘‘anticipates’’ or similar expressions that concern our strategy, plans or intentions. Any statements we make relating to our future operations, performance and results, and anticipated liquidity are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may change at any time, and, therefore, our actual results may differ materially from those we expected. We derive most of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and, of course, it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, including, without limitation, in conjunction with the forward-looking statements included in this Quarterly Report on Form 10-Q, are disclosed in “Item 1-Business, Item 1A – Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 27, 2025, and Part II, Item 1A of this Report.
We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. Our MD&A should be read in conjunction with our Form 10-K (including the information presented therein under the caption Risk Factors), together with our Quarterly Reports on Forms 10-Q and other publicly available information. All amounts herein are unaudited.
Our Company
Through our Fintech segment, we provide next generation blockchain-powered technologies to enable a migration to a new global financial paradigm, and, through our Biotechnology segment, we are focused on finding treatments for conditions that cause chronic pain and bringing to market drugs with non-addictive and non-sedative pain-relieving properties.
During the periods disclosed in this Quarterly Report, we operated three reportable segments:
Fintech
Our Fintech segment provides next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets. The Alt5 Canada portion of this segment is presented as discontinued operations for the 13 and 39 weeks ended September 26, 2026, and September 27, 2025.
Biotechnology
Our Biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. We have previously announced our intention to capitalize a subsidiary with certain of our biotechnology assets, acquire an additional biotechnology asset, and then engage in a financing of that subsidiary. The short-term intended result of that series of transactions would be for to decouple it from us so that it would operate on a stand-alone basis. The Biotech segment is being presented as discontinued operations for the 13 and 39 weeks ended September 26, 2026, and September 27, 2025. In connection with our previously announced, prospective spinoff of that subsidiary, we recently initiated serious discussions with two different public companies regarding a proposed transaction through which Drew would become a publicly traded entity. The terms currently under discussion contemplate a transaction valuation of Drew of approximately $200 million. Consummation of any spinoff transaction would be subject to the parties’ satisfactory completion of due diligence, negotiation, preparation, and execution and delivery of definitive agreements, and receipt of required regulatory and equity holder approvals, among other items. There can be no assurance that the parties will consummate any transaction at that estimated, approximate valuation, any other greater or lesser valuation, or at all.
Corporate and Other
In August 2025, we closed a $1.5 billion registered direct offering and concurrent private placement to launch our WLFI Treasury Strategy. This “capital with a purpose” financing positioned the Company as one of the most significant institutional holders of WLFI, securing a meaningful stake in the native governance token of the World Liberty Financial ecosystem.
Our policy remains a committed long-term “HODL” approach. We have successfully used our WLFI tokens as collateral for loans, enabling us to access cash while retaining exposure to the tokens. We expect to continue using eligible tokens as collateral to access cash, subject to applicable contractual restrictions, lender availability and collateral requirements. We are also in the process of taking advantage of new staking capabilities on the WLFI platform and expect to generate additional revenue from staking activities. The timing and amount of staking revenue will depend on the implementation of these activities and the platform’s terms and performance. Future acquisitions may also be funded through operating cash flows, structured debt and selective capital raises. Token sales remain restricted to liquidity requirements or material portfolio rebalancing events.
Our Corporate and Other segment consists of WLFI assets, including any additions, redemptions, or mark-to-market changes in value, are recorded within the Company’s Corporate and Other segment.
Our Corporate and Other segment consists of certain corporate general and administrative costs.
| 30 |
For the Thirteen Weeks Ended September 26, 2026 and September 27, 2025
Results of Operations
The following table presents selected operating results (in thousands). The 2025 comparisons have been recast to present ALT5 Canada and Biotechnology within discontinued operations.
| 13 Weeks Ended | 13 Weeks Ended | |||||||
| September 26, 2026 | September 27, 2025 | |||||||
| Statement of Operations Data: | ||||||||
| Revenue | $ | 248 | $ | 913 | ||||
| Gross profit | 88 | 448 | ||||||
| Selling, general and administrative expenses | 5,524 | 12,566 | ||||||
| Interest (expense), net | (469 | ) | (359 | ) | ||||
| Unrealized loss on cryptocurrency assets | (3,841 | ) | 72,836 | |||||
| Net loss from continuing operations before provision of income taxes | (12,867 | ) | 60,595 | |||||
| Net loss from discontinued operations before provision of income taxes | $ | (8,943 | ) | $ | (3,910 | ) | ||
The following tables present continuing-operations revenue and gross profit by business category (in thousands). Discontinued operations are excluded from the continuing totals.
| 13 Weeks Ended | 13 Weeks Ended | |||||||||||||||
| September 26, 2026 | September 27, 2025 | |||||||||||||||
| Net Revenue | Percent of Total | Net Revenue | Percent of Total | |||||||||||||
| Revenue | ||||||||||||||||
| Fintech | $ | 248 | 100 | % | $ | 913 | 100 | % | ||||||||
| Corporate & Other | — | — | % | — | — | % | ||||||||||
| Discontinued operations | — | — | % | — | — | % | ||||||||||
| Total revenue | $ | 248 | 100 | % | $ | 913 | 100 | % | ||||||||
| 13 Weeks Ended | 13 Weeks Ended | |||||||||||||||
| September 26, 2026 | September 27, 2025 | |||||||||||||||
| Gross Profit | Gross Profit Percentage | Gross Profit | Gross Profit Percentage | |||||||||||||
| Gross Profit | ||||||||||||||||
| Fintech | $ | 88 | 35.5 | % | $ | 448 | 49.1 | % | ||||||||
| Corporate & Other | — | — | % | — | — | % | ||||||||||
| Discontinued operations | — | — | % | — | — | % | ||||||||||
| Total gross profit | $ | 88 | 35.5 | % | $ | 448 | 49.1 | % | ||||||||
Revenue
Continuing-operations revenue decreased by approximately $0.7 million, or 72.8%, to $0.2 million for the 13 weeks ended September 26, 2026, from $0.9 million in the comparable 2025 period. The comparison reflects Mswipe within continuing operations and excludes the Alt5 Canada business disposed of during the quarter.
Gross Profit
Continuing-operations gross profit decreased by approximately $0.4 million to $0.1 million for the 13 weeks ended September 26, 2026, from $0.4 million in the comparable 2025 period. Gross margin decreased to 35.5% from 49.1%, reflecting the relationship between transaction revenue and related costs in the continuing business.
| 31 |
Selling, General and Administrative Expense
Continuing-operations selling, general and administrative expenses decreased by approximately $7.0 million to $5.5 million for the 13 weeks ended September 26, 2026, from $12.6 million on the recast 2025 basis. Current-period expenses comprise approximately $0.5 million for Fintech and $5.1 million for Corporate and Other. Fintech comprises Mswipe; Corporate and Other includes parent-company, digital-treasury and corporate/consolidating expenses.
Unrealized Loss on Cryptocurrency Assets
An unrealized loss on cryptocurrency assets of approximately $3.8 million was recorded for the 13 weeks ended September 26, 2026, compared with an unrealized gain of $72.8 million in the comparable 2025 period. The 2026 loss reflects the quarter’s change in the fair value of WLFI tokens and is a noncash item.
Other Income (Expense)
Other expense, net, was $3.2 million for the thirteen weeks ended September 26, 2026, compared with other income of $2,000 in the comparable 2025 period. The current-period amount includes a $0.9 million accumulated-deficit reconciliation adjustment recorded in continuing operations. Canada operating and disposal effects are presented in discontinued operations.
Segment Performance
The continuing businesses comprise Fintech and Corporate and Other. ALT5 Canada, sold in August 2026, and the Biotechnology business are presented within discontinued operations in the comparisons below.
Operating income or loss is measured before net interest, other income and expense, and income taxes. The Total columns below include the separately identified discontinued operations (in thousands).
| 13 Weeks Ended September 26, 2026 | 13 Weeks Ended September 27, 2025 | |||||||||||||||||||||||||||||||
| Fintech | Corporate and Other | Discontinued operations | Total | Fintech | Corporate and Other | Discontinued operations | Total | |||||||||||||||||||||||||
| Revenue | $ | 248 | $ | — | $ | 596 | $ | 844 | $ | 913 | $ | — | $ | 6,662 | $ | 7,575 | ||||||||||||||||
| Cost of revenue | 160 | — | 20 | 180 | 465 | — | 4,487 | 4,952 | ||||||||||||||||||||||||
| Gross profit | 88 | — | 576 | 664 | 448 | — | 2,175 | 2,623 | ||||||||||||||||||||||||
| Selling, general and administrative expenses | 473 | 5,051 | (84 | ) | 5,440 | 448 | 12,118 | 8,645 | 21,211 | |||||||||||||||||||||||
| Operating income (loss) | (385 | ) | (5,051 | ) | 660 | (4,776 | ) | — | (12,118 | ) | (6,470 | ) | (18,588 | ) | ||||||||||||||||||
Fintech Segment
Following the sale of ALT5 Canada, the continuing Fintech business consists of Mswipe. Continuing-operations revenue was approximately $0.2 million and gross profit was approximately $0.1 million for the 13 weeks ended September 26, 2026, with a gross margin of 35.5%.
Corporate and Other Segment
Corporate and Other generated no revenue in the 13-week periods ended September 26, 2026 and September 27, 2025. Its activities include corporate costs and the WLFI treasury program.
Discontinued Operations
Discontinued operations include ALT5 Canada and Biotechnology.
| 32 |
For the Thirty-Nine Weeks Ended September 26, 2026 and September 27, 2025
Results of Operations
The following table presents selected operating results (in thousands). The 2025 comparisons have been recast to present ALT5 Canada and Biotechnology within discontinued operations.
| 39 weeks Ended | 39 weeks Ended | |||||||
| September 26, 2026 | September 27, 2025 | |||||||
| Statement of Operations Data: | ||||||||
| Revenue | $ | 934 | $ | 1,235 | ||||
| Gross profit | 546 | 446 | ||||||
| Selling, general and administrative expenses | 10,723 | 15,090 | ||||||
| Interest expense, net | (1,000 | ) | (858 | ) | ||||
| Unrealized loss on cryptocurrency assets | (637,222 | ) | 72,836 | |||||
| Loss from continuing operations before provision of income taxes | (649,757 | ) | 57,490 | |||||
| Loss from discontinued operations before provision of income taxes | (15,326 | ) | (9,972 | ) | ||||
The following tables present continuing-operations revenue and gross profit by business category (in thousands). Discontinued operations are excluded from the continuing totals.
| 39 weeks Ended | 39 weeks Ended | |||||||||||||||
| September 26, 2026 | September 27, 2025 | |||||||||||||||
| Net Revenue | Percent of Total | Net Revenue | Percent of Total | |||||||||||||
| Revenue | ||||||||||||||||
| Fintech | $ | 934 | 100 | % | $ | 1,235 | 100 | % | ||||||||
| Corporate & Other | — | — | % | — | — | % | ||||||||||
| Discontinued operations | — | — | % | — | — | % | ||||||||||
| Total revenue | $ | 934 | 100 | % | $ | 1,235 | 100 | % | ||||||||
| 39 weeks Ended | 39 weeks Ended | |||||||||||||||
| September 26, 2026 | September 27, 2025 | |||||||||||||||
| Gross Profit | Gross Profit Percentage | Gross Profit | Gross Profit Percentage | |||||||||||||
| Gross Profit | ||||||||||||||||
| Fintech | $ | 546 | 58.5 | % | $ | 446 | 36.1 | % | ||||||||
| Corporate & Other | — | — | % | — | — | % | ||||||||||
| Discontinued operations | — | — | % | — | — | % | ||||||||||
| Total gross profit | $ | 546 | 58.5 | % | $ | 446 | 36.1 | % | ||||||||
Revenue
Continuing-operations revenue decreased by approximately $0.3 million, or 24.4%, to $0.9 million for the 39 weeks ended September 26, 2026, from $1.2 million on the recast 2025 basis. Both periods exclude ALT5 Canada from continuing operations.
Gross Profit
Continuing-operations gross profit increased by approximately $0.1 million to $0.5 million for the 39 weeks ended September 26, 2026, from $0.4 million on the recast 2025 basis. Gross margin increased to 58.5% from 36.1%.
Selling, General and Administrative Expense
Continuing-operations selling, general and administrative expenses decreased by approximately $4.4 million to $10.7 million for the 39 weeks ended September 26, 2026, from $15.1 million on the recast 2025 basis. Current-period expenses comprise approximately $1.0 million for Fintech and $9.7 million for Corporate and Other.
| 33 |
Interest Expense, net
Net interest expense from continuing operations increased by approximately $0.1 million to $1.0 million for the 39 weeks ended September 26, 2026, from $0.9 million on the recast 2025 basis. This comparison excludes interest attributable to discontinued operations.
Unrealized Loss on Cryptocurrency Assets
An unrealized loss on cryptocurrency assets of approximately $637.2 million was recorded for the 39 weeks ended September 26, 2026, compared with an unrealized gain of $72.8 million in the comparable 2025 period. At September 26, 2026, the reported 7,283,585,650 WLFI tokens were valued at approximately $417.4 million using a closing price of $0.05731263 per token. The fair-value loss is noncash.
Other Income (Expense)
Other expense, net, was $1.6 million for the thirty-nine weeks ended September 26, 2026, compared with other expense of $78,000 in the comparable 2025 period. The year-to-date amount includes the reconciliation adjustment described above.
Segment Performance
The continuing businesses comprise Fintech and Corporate and Other. ALT5 Canada and Biotechnology are presented within discontinued operations for the periods compared below.
Operating income or loss is measured before net interest, other income and expense, and income taxes. The Total columns below include the separately identified discontinued operations (in thousands).
| 39 weeks Ended September26 , 2026 | 39 weeks Ended September 27, 2025 | |||||||||||||||||||||||||||||||
| Fintech | Corporate and Other | Discontinued operations | Total | Fintech | Corporate and Other | Discontinued operations | Total | |||||||||||||||||||||||||
| Revenue | $ | 934 | $ | — | $ | 7,035 | $ | 7,969 | $ | 1,235 | $ | — | $ | 18,232 | $ | 19,467 | ||||||||||||||||
| Cost of revenue | 388 | — | 989 | 1,377 | 789 | — | 10,689 | 11,478 | ||||||||||||||||||||||||
| Gross profit | 546 | — | 6,046 | 6,592 | 446 | — | 7,543 | 7,989 | ||||||||||||||||||||||||
| Selling, general and administrative expenses | 1,036 | 9,687 | 5,483 | 16,206 | 689 | 14,401 | 16,409 | 31,499 | ||||||||||||||||||||||||
| Operating income (loss) | (490 | ) | (9,687 | ) | 563 | (9,614 | ) | (243 | ) | (14,401 | ) | (8,866 | ) | (23,510 | ) | |||||||||||||||||
Fintech Segment
The continuing Fintech business consists of Mswipe. Continuing-operations revenue was approximately $0.9 million and gross profit was approximately $0.5 million for the 39 weeks ended September 26, 2026, with a gross margin of 58.5%.
Corporate and Other Segment
Corporate and Other generated no revenue in either 39-week period. Its activities include corporate costs and the WLFI treasury program.
Discontinued Operations
Discontinued operations include ALT5 Canada and Biotechnology.
Liquidity and Capital Resources
Overview
At September 26, 2026, cash was approximately $2.6 million, compared with opening consolidated cash of approximately $2.3 million. The Company also held a $1.3 million certificate of deposit, classified separately from cash. The cash bridge includes approximately $1.0 million of cash disposed of with ALT5 Canada. We have successfully obtained loans secured by WLFI tokens and expect to continue using eligible tokens as collateral to access cash, subject to contractual restrictions and collateral requirements. We are also pursuing new staking capabilities on the WLFI platform and expect additional revenue from those activities. Subsequent to quarter end, the Company received a margin call in connection with the Concrete arrangement as described in Note 22.
| 34 |
Cash Flows
Net cash used in operating activities was $21.0 million for the thirty-nine weeks ended September 26, 2026. Unrealized cryptocurrency losses of approximately $637.2 million and the deferred income tax benefit are noncash reconciliation items.
Net cash used in investing activities was $2.3 million. Investing cash flows comprise $5.0 million of certificate-of-deposit purchases, $3.7 million of principal redemptions and $1.0 million of cash disposed of with ALT5 Canada.
Net cash provided by financing activities was $16.7 million, comprising $18.0 million of borrowing proceeds, offset by $0.8 million of note repayments and $0.5 million of treasury-share purchases.
Future Sources of Cash; Phase 2b Trials, New Acquisitions, Products, and Services
We may require additional debt financing and/or capital to finance new acquisitions, conduct our Phase IIb clinical trials for our Biotechnology segment, or consummate other strategic investments in our business. No assurance can be given any financing obtained may not further dilute or otherwise impair the ownership interest of our existing stockholders.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Market Risk and Impact of Inflation
Interest Rate Risk. We do not believe there is any significant risk related to interest rate fluctuations on our short and long-term fixed rate debt.
We do not hold any derivative financial instruments, nor do we hold any securities for trading or speculative purposes.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Evaluation of Disclosure control and Procedures. We carried out an evaluation, under the supervision, and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of September 26, 2026, the period covered in this report, our disclosure controls and procedures were not effective to ensure that information required to be disclosed in reports filed under the Exchange is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure due to material weaknesses in internal control over financial reporting further described below.
Despite the identified material weaknesses, management concluded that the consolidated financial statements included in this Quarterly Report on Form 10-Q present fairly, in all material respects, the financial position, results of operations and cash flows for the periods disclosed in conformity with GAAP. LJ Soldinger Associates, LLC, the Company’s independent registered public accounting firm, issued an unqualified opinion on our consolidated financial statements as of and for the year ended December 27, 2025. They were not engaged to perform, and did not perform, an audit of internal control over financial reporting. The control deficiencies contributed to errors that required restatement of the Company’s 2024 consolidated financial statements, as described in the fiscal 2025 Annual Report on Form 10-K.
Management’s Report on Internal Control Over Financial Reporting. Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)). Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
| 35 |
The Company’s management, including our CEO and CFO, do not expect that the Company’s disclosure controls and procedures or the Company’s internal control over financial reporting will prevent or detect all errors and all fraud. A control system, regardless of how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system will be met. These inherent limitations include the following: judgments in decision-making can be faulty, and control and process breakdowns can occur because of simple errors or mistakes, controls can be circumvented by individuals, acting alone or in collusion with each other, or by management override. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.
Our management assessed the effectiveness of our internal control over financial reporting as of September 26, 2026. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) of 2013 regarding Internal Control – Integrated Framework. Based on our assessment using those criteria, our management concluded that our internal control over financial reporting were not effective as of September 26, 2026. Management noted the following deficiencies that management believes to be material weaknesses:
| ● | The Company does not have a properly documented internal control system in accordance with the requirements of the Committee on Sponsoring Organizations (“COSO”) or some similarly appropriate internal control methodology or formal documentation of the Company’s systems of internal control. This control deficiency contributed to errors that necessitated a restatement of the Company’s 2024 consolidated financial statements and represents a material weakness in internal control over financial reporting. | |
| ● | The Company did not properly apply ASC 820 in valuing certain equity instruments issued as consideration in a business combination. The Company recorded and adjustment to correct the error. |
In response to the above identified weaknesses in our internal control over financial reporting, we plan to improve the documentation of our internal control policies and procedures and develop an internal testing plan to document our evaluation of effectiveness of the internal controls. We expect to conclude these remediation initiatives during the fiscal year ended December 26, 2026. We continue to evaluate testing of our internal control policies and procedures, including assessing internal and external resources that may be available to complete these tasks, but do not know when these tasks will be completed.
A material weakness (within the meaning of PCAOB Auditing Standard No. 5) is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of the company’s financial reporting.
| ● | The Company improperly recorded an adjustment that duplicated certain fees and overstated revenue. The Company recorded an adjustment to correct the error. | |
| ● | The Company used an incorrect grant-date fair value in measuring certain equity awards. The amount of the misstatement was not material. | |
| ● | The Company did not appropriately record certain qualifying equity issuance costs as a reduction of equity and instead recognized them in the income statement. The amount of the resulting misstatement was not material. |
This Quarterly Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management’s report in this Quarterly Report.
Changes in Internal Control Over Financial Reporting. There were no changes in the Company’s internal control over financial reporting identified in management’s evaluation pursuant to Rule 13a-15and 15d-15 of the Exchange Act that occurred during the period ended September 26, 2026 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
| 36 |
PART II. Other Information
Item 1. Legal Proceedings
The information in response to this item is included in Note 14, Commitments and Contingencies, to the Consolidated Financial Statements included in Part I, Item 1, of this Form 10-Q.
Item 1A. Risk Factors
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.
Item 2. Unregistered Sales of Equity Securities and Use of funds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information.
None.
Item 6. Exhibits.
Index to Exhibits
Exhibit Number |
Exhibit Description | Form | File Number |
Exhibit Number |
Filing Date | |||||
| 31.1 | * | Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||||||||
| 31.2 | * | Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||||||||
| 32.1 | * | Certification of the President and Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | ||||||||
| 32.2 | * | Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | ||||||||
| 101.INS | * | Inline XBRL Instance Document | ||||||||
| 101.SCH | * | Inline XBRL Taxonomy Extension Schema Document | ||||||||
| 101.CAL | * | Inline XBRL Taxonomy Extension Calculation Linkbase Document | ||||||||
| 101.DEF | * | Inline XBRL Taxonomy Extension Definition Linkbase Document | ||||||||
| 101.LAB | * | Inline XBRL Taxonomy Extension Label Linkbase Document | ||||||||
| 101.PRE | * | Inline XBRL Taxonomy Extension Presentation Linkbase Document | ||||||||
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
* Filed herewith.
| 37 |
SIGNATURES
Pursuant to the requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on our behalf by the undersigned, thereunto duly authorized.
| AI Financial Corporation | |||
| (Registrant) | |||
| Date: | November 10, 2026 | By: | /s/ Tony Isaac |
| Tony Isaac | |||
| Chief Executive Officer | |||
| (Principal Executive Officer) | |||
| Date: | November 10, 2026 | By: | /s/Steven M. Plumb |
| Steven M. Plumb | |||
| Chief Financial Officer | |||
| (Principal Financial and Accounting Officer) | |||
| 38 |
Exhibit 31.1
CERTIFICATIONS:
I, Tony Isaac, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q of AI Financial Corporation; | |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
| b. | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
| c. | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| d. | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a. | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and | |
| b. | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: November 10, 2026 | /s/ Tony Isaac |
| Tony Isaac | |
| Chief Executive Officer |
Exhibit 31.2
CERTIFICATIONS:
I, Steven Plumb, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q of AI Financial Corporation; | |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
| 4. | The registrant’s other certifying officer (s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
| b. | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
| c. | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and | |
| d. | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a. | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and | |
| b. | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: November 10, 2026 | /s/ Steven M. Plumb |
| Steven M. Plumb | |
| Chief Financial Officer |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. §1350 (as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002), the undersigned Chief Executive Officer of AI Financial Corporation (the “Company”) hereby certifies that the Quarterly Report on Form 10-Q of the Company for the period ended September 26, 2026 (the “Report”) fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: November 10, 2026 | /s/ Tony Isaac |
| Tony Isaac | |
| Chief Executive Officer |
The certification set forth above is being furnished as an exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report as a separate disclosure document of the Company or the certifying officers.
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. §1350 (as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002), the undersigned Chief Financial Officer of AI Financial Corporation (the “Company”) hereby certifies that the Quarterly Report on Form 10-Q of the Company for the period ended September 26, 2026 (the “Report”) fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: November 10, 2026 | /s/ Steven M. Plumb |
| Steven M. Plumb | |
| Chief Financial Officer |
The certification set forth above is being furnished as an exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report as a separate disclosure document of the Company or the certifying officers.
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.